Anika Therapeutics Inc. Common Stock (ANIK)

FairStock Score: 66/100 — STEADY

Key Financials

Strengths

• Generates $6 million in annual free cash flow (2.8% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.19, providing financial flexibility
• Altman Z-Score of 4.0 confirms minimal bankruptcy risk and strong solvency
• Revenue growth of 2473.3% demonstrates strong top-line momentum

AI Analysis

Anika Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $225 million. The business generates $116 million in annual revenue with a 0.3% net margin and $6 million in free cash flow. From a quality standpoint, Anika shows solid Piotroski F-Score of 7/9 and healthy Altman Z-Score of 4.0. On valuation, the stock is 1.8% FCF yield. Growth dynamics show revenue growing at 2473.3% and profit growth of 101.3%. Our composite FairStock Score of 66/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Anika's 2473% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $6 million in annual free cash flow (2.8% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer